Vaccines against pathogens can cut global antibiotic usage by 22%
Vaccines against 24 pathogens could cut the number of antibiotics needed to fight antimicrobial resistance by 2.5 billion daily doses or 22% globally,.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Vaccines against 24 pathogens could cut the number of antibiotics needed to fight antimicrobial resistance by 2.5 billion daily doses or 22% globally,.
HQ Team October 10, 2024: A recent study has raised concerns about the safety of topical benzoyl peroxide (BPO) products used for treating.
HQ Team October 10, 2024: A study published in Nature Communications discusses a novel water-soluble prodrug technology called Sol-moiety, which enhances the oral bioavailability of.
As Hurricane Milton looms large over the Florida coast, weather climate researchers said rainfall caused by Hurricane Helene, which struck two weeks before,.
Dengue cases in the Americas Region exceeded the number of cases historically reported in a year, as compared to all previously recorded years,.
GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season.
Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered.
Glaciers suffered the largest mass loss in 50 years as last year marked the driest for global rivers in 33 years, according to.
HQ Team October 8, 2024:Humanity is hitting the upper limit of life expectancy, according to a new study. Medical advances have led to.
Johnson and Johnson discontinued a study of an investigational drug to treat bladder cancer after it failed to yield desired results